Enhancement of the immune response via the facilitation of dendritic cell maturation by CD-205 Receptor-mediated Long-circling liposomes acting as an antigen and astragalus polysaccharide delivery system

• Published in: International immunopharmacology 2023-06, Vol.119, p.110242-110242, Article 110242
• Main Authors: Liu, Qianqian, Zhang, Xinnan, Chai, Dongkun, Li, Hangyu, Li, Sheng, Wu, Daiyan, Zhang, Linzi, Liu, Ziwei, Feng, Yangyang, Tang, Feng, Feng, Haibo
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic; Antigens; Astragalus Plant; Astragalus Polysaccharide; CD-205 Receptor; Cell Differentiation; Dendritic Cells; Drug Delivery System; Immunoglobulin G; Liposomes; Liposomes - metabolism; Long-circulating; Lymphocyte Activation; Ovalbumin; Polysaccharides - pharmacology
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2023.110242

[Display omitted] •iLPSM can carry large amounts of OVA and be effectively internalized by macrophage.•iLPSM can promote the production of total antibodies and antibody subclasses.•iLPSM can enhance Thl and Th2 cell responses at the same time.•iLPSM promote DCs maturation and improve antigen presentation efficiency. CD-205 receptor-mediated dendritic cell (DC) targeting liposomes are commonly used as a delivery system for inducing a strong T-cell immune response or specific immune tolerance. This delivery system can carry both the antigen and adjuvant, thereby modulating DC maturation and also activating the T-cell response. In order to maximize the desired therapeutic effects of Astragalus polysaccharides (APS) and induce an efficient cellular and humoral immune response against the antigen, ovalbumin (OVA) and APS were encapsulated in long-circling liposomes conjugated with anti-CD-205 receptor antibodies to produce CD-205-targeted liposomes (iLPSM). We explored using a series of experiments evaluating the targeting efficiency of iLPSM. In vitro, iLPSM nanoparticles promoted the proliferation of macrophages, and the nanoparticles were rapidly phagocytized by macrophages. In vivo, iLPSM significantly improved the antibody titers of OVA-specific IgG and IgG, isotypes cytokine production, and T and B lymphocyte differentiation. Furthermore, iLPSM facilitated the maturation of DCs. In addition, iLPSM nanoparticles could prolong the retention time of nanoparticles at the injection site, leading to a strong, sustained immune response. These results show that the CD-205 antibody successfully binds to the corresponding cell receptor.